The global dengue vaccine market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Dengue fever is an infectious disease spread by mosquitos that affects both animals and humans. It is caused by the dengue virus, which belongs to the Flaviviridae family and genus Flavivirus. It spreads from one person to another through the bite of an infected Aedes Aegypti mosquito. Dengue fever is characterized by a high temperature, exhaustion, headache, diarrhea, muscle discomfort, skin rashes, anemia, and vomiting. Seizures, yellow skin, and unconsciousness are among symptoms of dengue fever in its most severe form. It has a high death rate and can lead to significant neurological problems. Dengue fever causes CNS symptoms such as aberrant neurological signals, altered consciousness, delirium, and generalized and localized convulsions.
To Request a Sample of our Report on Dengue Vaccine Market: https://www.omrglobal.com/request-sample/dengue-vaccine-market
The key companies operating in the industry are highly inclined towards the adoption of different growth strategies including partnerships and collaborations, mergers and acquisitions, geographical expansion, and new product launches, to remain competitive in the marketplace. For instance, Takeda Pharmaceutical Company Limited announced in March 2021 that the European Medicines Agency (EMA) had accepted the Company’s filing packages for its dengue vaccine candidate (TAK-003), which is being investigated for the prevention of dengue due to any dengue virus serotype in people aged four to sixty. During the year 2021, Takeda filed regulatory documents in Argentina, Brazil, Colombia, Indonesia, Malaysia, Mexico, Singapore, Sri Lanka, and Thailand. The tetravalent dengue vaccine candidate (TAK-003) developed by Takeda is based on a live-attenuated dengue serotype 2 virus, which serves as the genetic “backbone” for all four vaccine viruses. TAK-003 produced immunological responses against all four dengue serotypes in both seropositive and seronegative subjects, which lasted for 48 months following vaccination, according to clinical Phase 2 results in children and adolescents. The vaccine was also shown to be generally safe and well tolerated.
Market Coverage
- The market number available for – 2021-2027
- Base year- 2021
- Forecast period- 2022-2028
Segment Covered-
- By Product
- By End-User
Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape- Sanofi S.A., Takeda Pharmaceutical Company Limited, Sun Pharmaceutical Industries Ltd, and Merck & Co. Inc., among others.
(Get 15% Discount on Buying this Report)
A full Report of Dengue Vaccine Market is Available @ https://www.omrglobal.com/industry-reports/dengue-vaccine-market
Global Dengue Vaccine Market Report by Segment
By Drug Type
- CYD-TDV [Dengvaxia]
- Others
By End-User
- Government Institutes,
- Specialty Clinics
- Hospitals
- Others
Global Dengue Vaccine Market Report by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
- Latin America
- Middle East & Africa
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
